Intensity Therapeutics, Inc. (INTS)
3.35
-0.03
(-0.89%)
USD |
NASDAQ |
Oct 16, 16:00
3.27
-0.08
(-2.39%)
After-Hours: 20:00
Intensity Therapeutics Total Liabilities (Quarterly) : 2.307M for June 30, 2026
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 2.307M |
| March 31, 2026 | 2.312M |
| December 31, 2025 | 2.251M |
| September 30, 2025 | 2.363M |
| June 30, 2025 | 2.259M |
| March 31, 2025 | 2.731M |
| December 31, 2024 | 1.865M |
| September 30, 2024 | 2.434M |
| June 30, 2024 | 3.328M |
| March 31, 2024 | 2.686M |
| December 31, 2023 | 4.133M |
| September 30, 2023 | 0.9049M |
| Date | Value |
|---|---|
| June 30, 2023 | 3.094M |
| March 31, 2023 | 6.914M |
| December 31, 2022 | 6.854M |
| September 30, 2022 | 5.419M |
| June 30, 2022 | 4.754M |
| March 31, 2022 | 4.501M |
| December 31, 2021 | 3.900M |
| September 30, 2021 | |
| June 30, 2021 | |
| March 31, 2021 | 1.827M |
| December 31, 2020 | 1.708M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 1.646B |
| Oncolytics Biotech, Inc. | 13.84M |
| Sangamo Therapeutics, Inc. | 78.92M |
| Sarepta Therapeutics, Inc. | 1.661B |
| Anixa Biosciences, Inc. | 1.873M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 11.52M |
| Shareholders Equity (Quarterly) | 9.214M |
| Debt to Equity Ratio | 0.0103 |
| Current Ratio | 5.002 |
| Net Debt Paydown Yield | 0.06% |